Betahistine PCD Pharma Franchise Company
Cafoli Lifecare offers a Betahistine range of 7 tablet formulations manufactured in WHO-GMP certified facilities. Distributors serving ENT and neurology prescribers can secure district-wise monopoly franchise rights for this established anti-vertigo molecule with full promotional support.
What is Betahistine?
Betahistine is a histamine analogue that acts as a weak H1 agonist and H3 antagonist. It improves microcirculation in the inner ear and reduces endolymphatic pressure, which relieves the vertigo, tinnitus and hearing disturbance of Meniere's disease and other vestibular disorders. Reference: PubChem - Betahistine.
Available Forms
The Cafoli Betahistine portfolio is offered as oral Tablets in the commonly prescribed strengths. Contact us for current pack presentations and trade offers.
Therapeutic Applications
Betahistine is prescribed for vertigo, especially vestibular vertigo and Meniere's disease, and for associated tinnitus and hearing loss. Prescribers include ENT specialists, neurologists, physicians and general practitioners managing dizziness and balance disorders.
Why Betahistine is a High-Potential Molecule for Distributors
Vertigo and dizziness are extremely common complaints across ENT, neurology and general practice, and betahistine is the default first-line prescription for vestibular vertigo. Because treatment courses are often prolonged and recurrences frequent, betahistine tablets deliver steady, repeat prescription volume that supports dependable distributor revenue.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Betahistine
- PubMed: betahistine in vertigo
- MedlinePlus: Meniere's disease
Our formulations of Betahistine find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: